Sir, Extended-spectrum b-lactamases (ESBLs) have emerged as an important mechanism of resistance in Gram-negative bacteria, presenting challenges on several fronts. Until recently most ESBL producers were nosocomial Klebsiella spp. with TEM or SHV enzyme mutants; but this pattern has now changed, with the spread of CTX-M ESBLs in community Escherichia coli as well as nosocomial Klebsiella spp.
Sir, Extended-spectrum b-lactamases (ESBLs) have emerged as an important mechanism of resistance in Gram-negative bacteria, presenting challenges on several fronts. Until recently most ESBL producers were nosocomial Klebsiella spp. with TEM or SHV enzyme mutants; but this pattern has now changed, with the spread of CTX-M ESBLs in community Escherichia coli as well as nosocomial Klebsiella spp. 1 Treatment failures and deaths have occurred when cephalosporins were used against infections caused by ESBL producers that appeared susceptible in vitro, meaning that routine susceptibility tests with individual b-lactams are unreliable and that direct ESBL detection tests are desirable. 2 From a clinical perspective, ESBL-producing organisms frequently possess multiple resistance determinants to non-b-lactam antibiotics, including aminoglycosides and fluoroquinolones, leaving an extremely limited range of treatment options. 1 The management of community urinary tract infections (UTIs) caused by ESBL producers can be particularly difficult, and the paucity of active oral agents (essentially nitrofurantoin and fosfomycin) may necessitate the administration of a parenteral carbapenem.
Mecillinam (amdinocillin), an oral penicillin with good in vitro activity against Enterobacteriaceae, often appears active in vitro against ESBL producers in standard MIC test conditions, but its efficacy against infections caused by producers is uncertain. 1 To investigate further, we undertook inoculum effect and synergy studies using 30 ESBL-producing E. coli and Klebsiella spp. These were selected to include representatives of current UK outbreak and non-clonal strains with CTX-M-15 enzymes, along with reference E. coli J62-1 and J53-2 transconjugants with TEM and SHV ESBLs. 1 Isolates were confirmed as ESBL producers using cefpodoxime and cefpodoxime plus clavulanic acid discs on Iso-Sensitest agar according to standard Health Protection Agency and BSAC methods. 3, 4 MICs were determined by agar dilution on Iso-Sensitest agar with or without clavulanate (GlaxoSmithKline, Brentford, UK) at 2 or 4 mg/L. Inocula were adjusted to comprise 10 4 cfu/spot, as in standard BSAC tests, or 10 6 cfu/ spot. The controls were E. coli NCTC 11954, with a classical TEM-1 b-lactamase, and E. coli NCTC 12241 (ATCC 25922), fully susceptible to b-lactams. Plates were incubated and results recorded in-line with standard BSAC protocols. 3 The combined results are summarized in Table 1 3 Addition of clavulanate reduced the MICs of mecillinam for ESBL producers, bringing the modal value, as determined with an inoculum of 10 6 cfu/spot, down from 8-16 mg/L to 0.03-0.06 mg/L, though a few producers remained more resistant, perhaps owing to production of overwhelming amounts of enzyme.
The raised mecillinam MICs at the higher inoculum and the MIC reductions achieved by clavulanate both suggest that the compound is not stable to ESBLs and should not be used in severe infections caused by producers. It may potentially be useful in uncomplicated lower UTIs caused by ESBL producers with low MICs, because of the high levels of mecillinam achieved in the urine, but clinical investigation is needed. While several recent reviews 5, 6 of mecillinam's potential in community UTI have appeared, they do not give clear guidance on the agent's relative efficacy in infections caused by ampicillin-susceptible and -resistant E. coli, although its lability to TEM-1 enzyme is well recognized. One Russian study, with only an abstract in English, does note that mecillinam was less efficacious against E. coli with R1 plasmid, which encodes TEM-1 enzyme, than against its plasmid-free counterpart in a murine septicaemia model. 7 Although mecillinam can show b-lactamase-independent synergy with penicillins that bind to penicillin-binding proteins (PBPs) 1 and 3, this seems unlikely to have interfered with the present interaction studies, both because no synergy was seen with the Correspondence b-lactamase-negative control and, secondly, because clavulanate, like mecillinam, has primary affinity for PBP-2 of E. coli.
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The simultaneous administration of oral mecillinam with a compound containing a b-lactamase inhibitor such as co-amoxiclav appears promising, based on the present in vitro data, but cannot be advocated for clinical use without clinical evaluation.
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